Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04102618
Recruitment Status : Recruiting
First Posted : September 25, 2019
Last Update Posted : June 22, 2020
Sponsor:
Collaborator:
SOLTI Breast Cancer Research Group
Information provided by (Responsible Party):
Oncolytics Biotech

Brief Summary:
The purpose of this study is to find out if pelareorep in combination with different therapies helps to reduce the growth of breast cancer cells and increase the immune system's response to cancer. This study will also help to understand what this treatment does to the tumor. In addition, the safety of the combination treatments with pelareorep will be evaluated.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: Pelareorep Drug: Letrozole Drug: Atezolizumab Drug: Trastuzumab Early Phase 1

Detailed Description:

This is a window of opportunity non-randomized exploratory study to evaluate the safety and anti-tumor immunogenicity of pelareorep -/+ atezolizumab in five different cohorts in women with operable early breast cancer.

After enrollment, pelareorep will be administered at 4.5 × 1010 TCID50 intravenously on days 1, 2, 8 & 9. Other therapies will be administered according to the assigned treatment cohort.

After an initial biopsy (diagnostic biopsy in most cases), a second biopsy will be performed on Day 3. Patients will continue the planned treatment until day 21(±5), when a third biopsy will be performed. This third biopsy can be the surgical specimen if patient was scheduled for primary surgery, or a core biopsy if patient will undergo neoadjuvant treatment.

Blood samples will be collected throughout the study at three time points, Day 1, Day 3, and End of Treatment.

Patients will receive treatment for 3 weeks prior to surgery or neoadjuvant therapy. Thereafter, patients will either be considered for definitive surgery or primary medical treatment (e.g. neoadjuvant chemotherapy) at the discretion of the treating physician. Surgery or biopsy prior to neoadjuvant chemotherapy should be done within 3 weeks (±5 days) from the start of the study treatment.

The end of study visit will be performed at the day of surgery. A safety follow-up, the end of study visit, will be done at 28 days (± 7 days) after the last dose of treatment received

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)
Actual Study Start Date : March 29, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Cohort 1
HR+/HER2-neg patients who will receive pelareorep plus letrozole
Biological: Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
Other Name: Previously REOLYSIN®

Drug: Letrozole
Oral dose of 2.5 mg/day starting on Day 3 for 13 days

Experimental: Cohort 2
HR+/HER2-neg patients who will receive pelareorep plus letrozole plus atezolizumab
Biological: Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
Other Name: Previously REOLYSIN®

Drug: Letrozole
Oral dose of 2.5 mg/day starting on Day 3 for 13 days

Drug: Atezolizumab
1200 mg administered intravenously on Day 3

Experimental: Cohort 3
TNBC patients who will receive pelareorep plus atezolizumab
Biological: Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
Other Name: Previously REOLYSIN®

Drug: Atezolizumab
1200 mg administered intravenously on Day 3

Experimental: Cohort 4
HER2+/HR+ patients who will receive pelareorep plus trastuzumab plus atezolizumab
Biological: Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
Other Name: Previously REOLYSIN®

Drug: Atezolizumab
1200 mg administered intravenously on Day 3

Drug: Trastuzumab
8mg/kg administered intravenously or 600mg subcutaneously on Day 3

Experimental: Cohort 5
HER2+/HR- patients who will receive pelareorep plus trastuzumab plus atezolizumab
Biological: Pelareorep
4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
Other Name: Previously REOLYSIN®

Drug: Atezolizumab
1200 mg administered intravenously on Day 3

Drug: Trastuzumab
8mg/kg administered intravenously or 600mg subcutaneously on Day 3




Primary Outcome Measures :
  1. Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with operable early breast cancer treated with pelareorep in combination with different therapies. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days). ]

    CelTIL score is a metric for quantifying broad changes to the tumor microenvironment and is calculated by the following equation:

    CelTIL score = -0.8 × tumor cellularity (in percent) + 1.3 × TILs (in percent). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect the reported values ranging from 0 to 100 points where an increase in CelTIL scores represent favorable changes to the tumor microenvironment.



Secondary Outcome Measures :
  1. Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with triple-negative breast cancer treated with pelareorep and atezolizumab. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days). ]

    CelTIL score is a metric for quantifying broad changes to the tumor microenvironment and is calculated by the following equation:

    CelTIL score = -0.8 × tumor cellularity (in percent) + 1.3 × TILs (in percent). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect the reported values ranging from 0 to 100 points where an increase in CelTIL scores represent favorable changes to the tumor microenvironment.


  2. Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with HR+/HER2- breast cancer treated with pelareorep and letrozole. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days). ]

    CelTIL score is a metric for quantifying broad changes to the tumor microenvironment and is calculated by the following equation:

    CelTIL score = -0.8 × tumor cellularity (in percent) + 1.3 × TILs (in percent). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect the reported values ranging from 0 to 100 points where an increase in CelTIL scores represent favorable changes to the tumor microenvironment.


  3. Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with HR+/HER2- breast cancer treated with pelareorep, letrozole, and atezolizumab [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days). ]

    CelTIL score is a metric for quantifying broad changes to the tumor microenvironment and is calculated by the following equation:

    CelTIL score = -0.8 × tumor cellularity (in percent) + 1.3 × TILs (in percent). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect the reported values ranging from 0 to 100 points where an increase in CelTIL scores represent favorable changes to the tumor microenvironment.


  4. Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with HR+/HER2+ breast cancer treated with pelareorep, trastuzumab, and atezolizumab. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days). ]

    CelTIL score is a metric for quantifying broad changes to the tumor microenvironment and is calculated by the following equation:

    CelTIL score = -0.8 × tumor cellularity (in percent) + 1.3 × TILs (in percent). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect the reported values ranging from 0 to 100 points where an increase in CelTIL scores represent favorable changes to the tumor microenvironment.


  5. Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with HR-/HER2+ breast cancer treated with pelareorep, trastuzumab, and atezolizumab. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery (day ~21 ± 5 days). ]

    CelTIL score is a metric for quantifying broad changes to the tumor microenvironment and is calculated by the following equation:

    CelTIL score = -0.8 × tumor cellularity (in percent) + 1.3 × TILs (in percent). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect the reported values ranging from 0 to 100 points where an increase in CelTIL scores represent favorable changes to the tumor microenvironment.


  6. To describe the safety and tolerability of the combinations of pelareorep and letrozole, pelareorep and atezolizumab, and pelareorep, trastuzumab and atezolizumab: as graded by the NCI CTCAE v. 4.03 [ Time Frame: During treatment and until the end of study visit done at 28 days (± 7 days) after the last dose of treatment received ]
    Type, incidence, severity (as graded by the NCI CTCAE v. 4.03), seriousness and attribution to the study medications of AEs and any laboratory abnormalities.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Patient Inclusion Criteria:

  1. Signed written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures and assessments.
  2. Female patients.
  3. Age ≥18 years. In cohorts 1 and 2 (patients with HR+/HER2 negative breast cancer), only postmenopausal* patient can be included.
  4. Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast, with all of the following characteristics:

    • At least 1 lesion that can be measured in at least 1 dimension with ≥ 10 mm in largest diameter measured by ultrasound and mammogram.
    • Documentation confirming the absence of distant metastasis (M0) as determined by institutional practice. Routine exams to discard metastases will be performed according to Investigator judgement but are mandatory in case of suspicion of metastatic disease.
    • Breast cancer eligible for primary surgery.
    • In the case of a multifocal tumor (defined as the presence of two or more foci of cancer within the same breast quadrant), the largest lesion must be ≥ 10 mm and designated the "target" lesion for all subsequent tumor evaluations and biopsies.
  5. Patient must have biopsiable disease.
  6. Histologically confirmed HER2 status and hormone receptors (ER and PgR) according to ASCO/CAP guidelines locally assessed.

    • Invasive TNBC defined as: ER and PR negative defined as IHC nuclear staining <1% AND HER2 negative.
    • HR+/HER2 negative defined as: ER and PR positive defined as IHC nuclear staining >1% AND HER 2 negatives.
    • HER2 positive defined as; IHC +++ or FISH positive.
  7. ECOG Performance Status of 0 or 1.
  8. Adequate organ function, as determined by the following laboratory tests, within 14 days prior to randomization:

    • Hematological

      • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
      • Platelet count ≥ 100 x 109/L
      • Hemoglobin ≥ 9 g/dL (red blood cell transfusion and/or erythropoietin allowed)
    • Renal

      o Serum creatinine ≤ 1.5 x upper limit of normal (ULN), or 24-hour creatinine clearance ≥ 60 mL/min for subject with creatinine levels > 1.5 x ULN. (Note: Creatinine clearance does not need to be determined if the baseline serum creatinine is within normal limits. Creatinine clearance should be calculated per institutional standard).

    • Hepatic

      • Serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with total bilirubin level > 1.5 x ULN
      • Aspartate aminotransferase (AST) ≤ 3 x ULN
      • Alanine aminotransferase (ALT) ≤ 3 x ULN
      • Coagulation International normalization ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN
      • Partial thromboplastin time (PTT) or activated PTT (aPTT) ≤ 1.5 x ULN
  9. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  10. Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to enrollment. If urine pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (only for cohorts 3 to 5 and pre-menopausal women or non-confirmed postmenopausal* status).

    • *postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.) OR
    • have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR
    • has a congenital or acquired condition that prevents childbearing.

Patient Exclusion Criteria

  1. Inoperable locally advanced or inflammatory (i.e., inoperable Stage III) breast cancer.
  2. Metastatic (Stage IV) breast cancer.
  3. Bilateral invasive breast cancer.
  4. Multicentric breast cancer, defined as the presence of two or more foci of cancer in different quadrants of the same breast.
  5. Prior therapy for breast cancer.
  6. Prior therapy with an anti- PD-1, anti- PD-L1, anti-PD-L2, anti-CD137 antibody, or anti-CTLA-4 antibody compound, Pelareorep or any other oncolytic viruses.
  7. Prior therapy with tumor vaccine
  8. History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other symptomatic autoimmune disease, or active autoimmune disease or syndrome that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) except vitiligo or resolved childhood asthma/atopy or evidence of clinically significant immunosuppression. Replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  9. Treated or untreated hyperthyroidism. Uncontrolled hypothyroidism (patients with controlled and asymptomatic hypothyroidism can be included)
  10. Received live vaccine within 28 days prior to enrollment.
  11. History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other malignancies with an expected curative outcome.
  12. Evidence of clinically significant immunosuppression such as the following:

    • diagnosis of immunodeficiency
    • concurrent opportunistic infection
    • receiving systemic immunosuppressive therapy (> 2 weeks) or within 7 days prior to the first dose of study treatment, including oral steroid doses > 10 mg/day of prednisone or equivalent. Subjects that require intermittent use of bronchodilators or local steroid injection will not be excluded from the study.
  13. Cardiopulmonary dysfunction as defined by:

    • Uncontrolled hypertension (systolic >150 mm Hg and/or diastolic > 100 mm Hg) despite optimal medical management.
    • Inadequately controlled angina or serious cardiac arrhythmia not controlled by adequate medication.
    • History of symptomatic congestive heart failure (CHF): Grade ≥ 3 per NCI CTCAE version 4.03 or Class ≥ II New York Health Association (NYHA criteria).
    • Myocardial infarction within 6 months prior to randomization.
    • Current dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy
  14. Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone fractures).
  15. Major surgical procedure or significant traumatic injury within approximately 28 days prior to enrollment or anticipation of the need for major surgery during the course of study treatment.
  16. Concurrent, serious, uncontrolled infections or current known infection with HIV or active hepatitis B and/or hepatitis C.
  17. Assessment by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  18. Known history of active Bacillus tuberculosis.
  19. History of significant co-morbidities that, in the judgment of the Investigator, may interfere with the conduction of the study, the evaluation of response, or with informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04102618


Contacts
Layout table for location contacts
Contact: Amparo Buenestado + 34 933 436 302 amparo.buenestado@gruposolti.org
Contact: Fernando Salvador + 34 933 436 302 fernando.salvador@gruposolti.org

Locations
Layout table for location information
Spain
ICO Badalona Recruiting
Badalona, Spain
Hospital Clínic de Barcelona Recruiting
Barcelona, Spain
Hospital Quirón Dexeus Recruiting
Barcelona, Spain
Hospital Moisés Broggi Recruiting
Esplugues De Llobregat, Spain
Hospital Fuenlabrada Recruiting
Madrid, Spain
Hospital La Paz Recruiting
Madrid, Spain
Hospital Puerta de Hierro de Majadahonda Recruiting
Madrid, Spain
Hospital Universitario 12 de Octubre Recruiting
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz Recruiting
Madrid, Spain
Hospital Clínico Universitario Virgen Arrixaca Recruiting
Murcia, Spain
Hospital Universitario Virgen Macarena Not yet recruiting
Sevilla, Spain
Hospital Clínico Universitario de Valencia Recruiting
Valencia, Spain
Instituto Valenciano de Oncología Recruiting
Valencia, Spain
Hospital Clínico Lozano Blesa Recruiting
Zaragoza, Spain
Sponsors and Collaborators
Oncolytics Biotech
SOLTI Breast Cancer Research Group
Layout table for additonal information
Responsible Party: Oncolytics Biotech
ClinicalTrials.gov Identifier: NCT04102618    
Other Study ID Numbers: REO 027
First Posted: September 25, 2019    Key Record Dates
Last Update Posted: June 22, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Oncolytics Biotech:
Breast
Breast Cancer
Primary Breast
Primary Breast Cancer
Pelareorep
Atezolizumab
Reovirus
Oncolytic virus
Letrozole
Early Breast Cancer
Triple-negative breast cancer
HR+ breast cancer
HER2+ breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Trastuzumab
Letrozole
Atezolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs